Voziyan Paul A, Khalifah Raja G, Thibaudeau Christophe, Yildiz Alaattin, Jacob Jaison, Serianni Anthony S, Hudson Billy G
Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, 1161 21st Avenue South, Nashville, TN 37232, USA.
J Biol Chem. 2003 Nov 21;278(47):46616-24. doi: 10.1074/jbc.M307155200. Epub 2003 Sep 15.
Hyperglycemic conditions of diabetes accelerate protein modifications by glucose leading to the accumulation of advanced glycation end-products (AGEs). We have investigated the conversion of protein-Amadori intermediate to protein-AGE and the mechanism of its inhibition by pyridoxamine (PM), a potent AGE inhibitor that has been shown to prevent diabetic complications in animal models. During incubation of proteins with physiological diabetic concentrations of glucose, PM prevented the degradation of the protein glycation intermediate identified as fructosyllysine (Amadori) by 13C NMR using [2-13C]-enriched glucose. Subsequent removal of glucose and PM led to conversion of protein-Amadori to AGE Nepsilon-carboxymethyllysine (CML). We utilized this inhibition of post-Amadori reactions by PM to isolate protein-Amadori intermediate and to study the inhibitory effect of PM on its degradation to protein-CML. We first tested the hypothesis that PM blocks Amadori-to-CML conversion by interfering with the catalytic role of redox metal ions that are required for this glycoxidative reaction. Support for this hypothesis was obtained by examining structural analogs of PM in which its known bidentate metal ion binding sites were modified and by determining the effect of endogenous metal ions on PM inhibition. We also tested the alternative hypothesis that the inhibitory mechanism involves formation of covalent adducts between PM and protein-Amadori. However, our 13C NMR studies demonstrated that PM does not react with the Amadori. Because the mechanism of interference with redox metal catalysis is operative under the conditions closely mimicking the diabetic state, it may contribute significantly to PM efficacy in preventing diabetic complications in vivo. Inhibition of protein-Amadori degradation by PM also provides a simple procedure for the isolation of protein-Amadori intermediate, prepared at physiological levels of glucose for relevancy, to study both the biological effects and the chemistry of post-Amadori pathways of AGE formation.
糖尿病的高血糖状况会加速葡萄糖导致的蛋白质修饰,从而导致晚期糖基化终产物(AGEs)的积累。我们研究了蛋白质-阿玛多利中间体向蛋白质-AGE的转化以及其被吡哆胺(PM)抑制的机制,吡哆胺是一种有效的AGE抑制剂,已被证明可在动物模型中预防糖尿病并发症。在用生理糖尿病浓度的葡萄糖孵育蛋白质的过程中,PM通过使用[2-¹³C]富集葡萄糖的¹³C NMR阻止了被鉴定为果糖基赖氨酸(阿玛多利)的蛋白质糖基化中间体的降解。随后去除葡萄糖和PM导致蛋白质-阿玛多利转化为AGE Nε-羧甲基赖氨酸(CML)。我们利用PM对阿玛多利后反应的这种抑制作用来分离蛋白质-阿玛多利中间体,并研究PM对其降解为蛋白质-CML的抑制作用。我们首先测试了一个假设,即PM通过干扰这种糖氧化反应所需的氧化还原金属离子的催化作用来阻断阿玛多利向CML的转化。通过检查PM的结构类似物(其中其已知的双齿金属离子结合位点被修饰)以及确定内源性金属离子对PM抑制的影响,获得了对该假设的支持。我们还测试了另一种假设,即抑制机制涉及PM与蛋白质-阿玛多利之间形成共价加合物。然而,我们的¹³C NMR研究表明PM不与阿玛多利反应。由于干扰氧化还原金属催化的机制在紧密模拟糖尿病状态的条件下起作用,它可能对PM在体内预防糖尿病并发症的功效有显著贡献。PM对蛋白质-阿玛多利降解的抑制也为分离蛋白质-阿玛多利中间体提供了一个简单的程序,该中间体在生理水平的葡萄糖下制备以具有相关性,用于研究AGE形成的阿玛多利后途径的生物学效应和化学性质。